Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Globus Medical Preps IPO, Sales Force Ramp Ahead Of Artificial Cervical Disc Approval

This article was originally published in The Gray Sheet

Executive Summary

Firm files for initial public stock offering, awaits PMA approval of its Secure-C artificial cervical disc.

You may also be interested in...

Financings In Brief

Globus Medical goes public. Exact Sciences nets $57.8 million from stock sale for cancer test. Cleveland Heart gets $30 million for artificial heart development. More financings.

New Guidance Outlining Total Artificial Disc Trial Design Issued

Investigational device exemption applications for total artificial disc systems should include plans for product durability testing and multi-center clinical trials with at least two years of follow-up, according to new FDA guidance

Making The Case For A Legislative Deal On Drug Pricing

Drawing on 24 years as a legislator and another 16 years as a leading lobbyist for biopharma, Jim Greenwood sees an opportunity for industry to put drug pricing behind us with a legislative compromise.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts